Ureylene naphthalene sulfonic acids

ABSTRACT

Ureylenebis-symmetrical-phenenylbiscarbonylimino-substituted phenylenecarbonylimino-tetranaphthalenepolysulfonic acid benzoic acid salts, and nitro- and amino-substituted phenylenebiscarbonylimino-substituted benzamido-phenylenedicarbonyl-dinaphthalenepolysulfonic acid benzoic acid salts which are intermediates for the preparation of the active ureides which have complement inhibiting activity.

BACKGROUND OF THE INVENTION

The term "complement" refers to a complex group of proteins in bodyfluids that, working together with antibodies or other factors, play animportant role as mediators of immune, allergic, immunochemical and/orimmunopathological reactions. The reactions in which complementparticipates take place in blood serum or in other body fluids, andhence are considered to be humoral reactions.

With regard to human blood, there are at present more than 11 proteinsin the complement system. These complement proteins are designated bythe letter C and by number: C1, C2, C3 and so on up to C9. Thecomplement protein C1 is actually an assembly of subunits designatedC1q, C1r and C1s. The numbers assigned to the complement proteinsreflect the sequence in which they become active, with the exception ofcomplement protein C4, which reacts after C1 and before C2. Thenumerical assignments for the proteins in the complement system weremade before the reaction sequence was fully understood. A more detaileddiscussion of the complement system and its role in body processes canbe found in, for example, Bull. World Health Org., 39, 935-938 (1968);Ann. Rev. Medicine, 19, 1-24 (1968); The John Hopkins Med. J., 128,57-74 (1971); Harvey Lectures, 66, 75-104 (1972); The New EnglandJournal of Medicine, 287, 452-454; 489-495; 545-549; 592-596; 642-646(1972); Scientific American, 229, (No. 5), 54-66 (1973); FederationProceedings, 32, 134-137 (1973); Medical World News, Oct. 11, 1974, pp.53-66; J. Allergy Clin. Immunol., 53, 298-302 (1974); Cold Spring HarborConf. Cell Proliferation 2/Proteases Biol. Control/229-241 (1975);Annals of Internal Medicine, 84, 580-593 (1976); "Complement: Mechanismsand Functions", Prentice-Hall, Englewood Cliffs, N.J. (1976).

The complement system can be considered to consist of three sub-systems:(1) a recognition unit (C1q) which enables it to combine with antibodymolecules that have detected a foreign invader; (2) an activation unit(C1r, C1s, C2, C4, C3) which prepares a site on the neighboringmembrane; and (3) and attack unit (C5, C6, C7, C8 and C9) which createsa "hole" in the membrane. The membrane attack unit is non-specific; itdestroys invaders only because it is generated in their neighborhood. Inorder to minimize damage to the host's own cells, its activity must belimited in time. This limitation is accomplished partly by thespontaneous decay of activated complement and partly by interference byinhibitors and destructive enzymes. The control of complement, however,is not perfect, and there are times when damage is done to the host'scells. Immunity is therefore a double-edged sword.

Activation of the complement system also accelerates blood clotting.This action comes about by way of the complement-mediated release of aclotting factor from platelets. The biologically active complementfragments and complexes can become involved in reactions that damage thehost's cells, and these pathogenic reactions can result in thedevelopment of immune-complex diseases. For example, in some forms ofnephritis, complement damages the basal membrane of the kidney,resulting in the escape of protein from the blood into the urine. Thedisease disseminated lupus erythematosus belongs in this category; itssymptoms include nephritis, visceral lesions and skin eruptions. Thetreatment of diphtheria or tetanus with the injection of large amountsof antitoxin sometimes results in serum sickness, an immune-complexdisease. Rheumatoid arthritis also involves immune complexes. Likedisseminated lupus erythematosus, it is an autoimmune disease in whichthe disease symptoms are caused by pathological effects of the immunesystem in the host's tissues. In summary, the complement system has beenshown to be involved with inflammation, coagulation, fibrinolysis,antibody-antigen reactions and other metabolic processes.

In the presence of antibody-antigen complexes the complement proteinsare involved in a series of reactions which may lead to irreversiblemembrane damage if they occur in the vicinity of biological membranes.Thus, while complement constitutes a part of the body's defensemechanism against infection it also results in inflammation and tissuedamage in the immunopathological process. The nature of certain of thecomplement proteins, suggestions regarding the mode of complementbinding to biological membranes and the manner in which complementeffects membrane damage are discussed in Annual Review in Biochemistry,38, 389 (1969).

A variety of substances have been disclosed as inhibiting the complementsystem, i.e., as complement inhibitors. For example, the compounds3,3'-ureylenebis-[6-(2-amino-8-hydroxy-6-sulfo-1-naphthylazo)]benzenesulfonicacid, tetrasodium salt (chlorazol fast pink), heparin and a sulphateddextran have been reported to have an anticomplementary effect, BritishJournal of Experimental Pathology, 33, 327-339 (1952). The compound8-(3-benzamido-4-methylbenzamido)naphthalene-1,3,5-trisulfonic acid(Suramin) is described as a competitive inhibitor of the complementsystem, Clin. Exp. Immunol., 10, 127-138 (1972). German Pat. No.2,254,893 or South African Pat. No. 727,923 discloses certain1-(diphenylmethyl)-4-(3-phenylallyl)piperazines useful as complementinhibitors. Other chemical compounds having complement inhibitingactivity are disclosed in, for example, Journal of Medicinal Chemistry,12, 415-419; 902-905; 1049-1052; 1053-1056 (1969); Canadian Journal ofBiochemistry, 47, 547-552 (1969); The Journal of Immunology, 93, 629-640(1964); The Journal of Immunology, 104, 279-288 (1970); The Journal ofImmunology, 106, 241-245 (1971); and The Journal of Immunology, 111,1061-1066 (1973).

It has been reported that the known complement inhibitorsepsilon-aminocaproic acid, Suramin and tranexamic acid all have beenused with success in the treatment of hereditary angioneurotic edema, adisease state resulting from an inherited deficiency or lack of functionof the serum inhibitor of the activated first component of complement(C1 inhibitor), The New England Journal of Medicine, 286, 808-812(1972). It has also been reported that the drug pentosan-poly-sulfoesterhas an anticomplementary activity on human serum both in vitro and invivo, as judged by the reduction in total hemolytic complement activity;Pathologie Biologie, 25, 33-36 (1977).

SUMMARY OF THE INVENTION

This invention is concerned with tetranaphthalene sulfonic acid ureylenesalts, having complement inhibiting activity, which are new compounds offormula I: ##STR1## wherein R is selected from the group consisting ofhydrogen and methyl; R₁ is selected from the group consisting ofhydrogen and carboxyl; A is a pharmaceutically acceptable salt cation.

A preferred embodiment of the instant invention consists of thosecompounds wherein R₁ is hydrogen; and R and A are as previously defined.

A second preferred embodiment of the instant invention consists of thosecompounds wherein R₁ is carboxyl; and R and A are as previously defined.

A most preferred embodiment of the second preferred embodiment consistsof those compounds wherein A is sodium.

This invention is also concerned with compounds of formula II: ##STR2##wherein R₂ is selected from the group consisting of nitro and amino; R₃is selected from the group consisting of hydrogen and methyl; R₄ isselected from the group consisting of hydrogen and carboxyl; and A isselected from the group consisting of alkali metal.

A preferred embodiment of the instant invention consists of thosecompounds wherein R₄ is hydrogen; and R₂, R₃ and A are as previouslydefined.

A second preferred embodiment of the instant invention consists of thosecompounds wherein R₄ is carboxyl; and R₂, R₃ and A are as previouslydefined.

The compounds described immediately above are useful as intermediatesfor the preparation of the complement inhibiting ureide compoundspreviously described. Certain of the instant intermediates possesscomplement inhibiting activity.

DESCRIPTION OF THE INVENTION

The compounds of the present invention may be prepared by the followingmethod outlined in Flow Chart A.

    ______________________________________                                        FLOW CHART A                                                                   ##STR3##                                                                      ##STR4##                                                                      ##STR5##                     (I)                                              ##STR6##                     (II)                                             ##STR7##                     (III)                                       

wherein X is selected from the group consisting of hydrogen and methyl;Y is selected from the group consisting of hydrogen and carbomethoxy; Zis selected from the group consisting of hydrogen and carboxyl; and A isselected from the group consisting of alkali metal.

The novel intermediate nitro (I) and amino (II) compounds of theinvention are prepared by reacting 8-amino-1,3,5-naphthalenetrisulfonicacid trialkali metal salt with the appropriate substituted nitro,substituted methyl or carbomethoxy aryl carbonyl chloride in basicaqueous medium for about 4 to about 5 hours. After acidification andneutralization, the solution is diluted with ethanol to provide thecorresponding substituted nitro, substituted methyl or carbomethoxy arylcarbonylimino substituted trialkali metal salt of1,3,5-naphthalenetrisulfonic acid. The methyl ester compound isconverted to the carboxylic acid by treatment with alkali metalhydroxide, acidification with dilute hydrochloric acid and precipitationfrom water:ethanol (1:10). Hydrogenation of the preceding nitrotrialkali metal salt using 10% palladium-carbon catalyst, filtration,concentration and treatment with absolute ethanol provides thecorresponding substituted amino, substituted methyl or carboxylic acidaryl carbonylimino substituted trialkali metal salt of1,3,5-naphthalenetrisulfonic acid. The amino trialkali metal saltdissolved in aqueous medium and neutralized to pH 7.2 is reacted with5-nitro-isophthaloyl chloride for about 2 to about 3 hours, in thepresence of alkali metal acetate. Filtration and evaporation of thefiltrate provides a residue which is dissolved in water, acidified to pH2.0-2.5 and diluted with absolute ethanol to precipitate thenitro-phenylenebiscarbonylimino substituted phenylenecarbonyliminodi-1,3,5-naphthalenetrisulfonic acid hexaalkali metal salt (I).Hydrogenation of (I) using 10% palladium-carbon catalyst in water,filtration and evaporation of the filtrate produces a residue which isdissolved in water and precipitated with absolute ethanol,(water:ethanol 1:10) to yield the amino-phenylenebiscarbonyliminosubstituted phenylenecarbonylimino di-1,3,5-naphthalenetrisulfonic acidhexaalkali salt (II). Phosgenation of (II) in aqueous medium with alkalimetal carbonate and adjustment to pH 7.0-7.2, filtration and evaporationprovides a residue. The residue is dissolved in water and reprecipitatedfrom water:ethanol (1:3) to provide the carbonyldiimino symmetricalphenenylbiscarbonylimino substituted phenylenecarbonyliminotetra-1,3,5-naphthalenetrisulfonic acid dodecaalkali metal salt (III).

The compounds of the present invention may be administered internally,e.g., orally, intra-articularly or parenterally, e.g., intra-articular,to a warm-blooded animal to inhibit complement in the body fluid of theanimal, such inhibition being useful in the amelioration or preventionof those reactions dependent upon the function of complement, such asinflammatory process and cell membrane damage induced byantigen-antibody complexes. A range of doses may be employed dependingon the mode of administration, the condition being treated and theparticular compound being used. For example, for intravenous orsubcutaneous use from about 5 to about 50 mg/kg/day, or every six hoursfor more rapidly excreted salts, may be used. For intra-articular usefor large joints such as the knee, from about 2 to about 20 mg/joint perweek may be used, with proportionally smaller doses for smaller joints.The dosage range is to be adjusted to provide optimum therapeuticresponse in the warm-blooded animal being treated. In general, theamount of compound administered can vary over a wide range to providefrom about 5 mg/kg to about 100 mg/kg of body weight of animal per day.The usual daily dosage for a 70 kg subject may vary from about 350 mg toabout 3.5 g. Unit doses of the acid or salt can contain from about 0.5mg to about 500 mg.

While in general the sodium salts of the acids of the invention aresuitable for parenteral use, other salts may also be prepared, such asthose of primary amines, e.g., ethylamine; secondary amines, e.g.,diethylamine or diethanol amine; tertiary amines, e.g., pyridine ortriethylamine or 2-dimethylaminomethyl-dibenzofuran; aliphatic diamines,e.g., decamethylenediamine; and aromatic diamines, can be prepared. Someof these are soluble in water, others are soluble in saline solution,and still others are insoluble and can be used for purposes of preparingsuspensions for injection. Furthermore as well as the sodium salt, thoseof the alkali metals, such as potassium and lithium; of ammonia; and ofthe alkaline earth metals, such as calcium or magnesium, may beemployed. It will be apparent, therefore, that these salts embrace, ingeneral derivatives of salt-forming cations.

In therapeutic use, the compounds of this invention may be administeredin the form of conventional pharmaceutical compositions. Suchcompositions may be formulated so as to be suitable for oral orparenteral administration. The active ingredient may be combined inadmixture with a pharmaceutically acceptable carrier, which carrier maytake a wide variety of forms depending on the form of preparationdesired for administration, i.e., oral or parenteral. The compounds canbe used in compositions such as tablets. Here, the principal activeingredient is mixed with conventional tabletting ingredients such ascorn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesiumstearate, dicalcium phosphate, gums, or similar materials as non-toxicpharmaceutically acceptable diluents or carriers. The tablets or pillsof the novel compositions can be laminated or otherwise compounded toprovide a dosage form affording the advantage of prolonged or delayedaction or predetermined successive action of the enclosed medication.For example, the tablet or pill can comprise an inner dosage and anouter dosage component, the latter being in the form of an envelope overthe former. The two components can be separated by an enteric layerwhich serves to resist disintegration in the stomach and permits theinner component to pass intact into the duodenum or to be delayed inrelease. A variety of materials can be used for such enteric layers orcoatings, such materials including a number of polymeric acids ormixtures of polymeric acids with such materials as shellac, shellac andcetyl alcohol, cellulose acetate and the like. A particularlyadvantageous enteric coating comprises a styrene maleic acid copolymertogether with known materials contributing to the enteric properties ofthe coating. The tablet or pill may be colored through the use of anappropriate non-toxic dye, so as to provide a pleasing appearance.

The liquid forms in which the novel compositions of the presentinvention may be incorporated for administration include suitableflavored emulsions with edible oils, such as, cottonseed oil, sesameoil, coconut oil, peanut oil, and the like, as well as elixirs andsimilar pharmaceutical vehicles. Sterile suspensions or solutions can beprepared for parenteral use. Isotonic preparations containing suitablepreservatives are also desirable for injection use.

The term dosage form, as described herein, refers to physically discreteunits suitable as unitary dosage for warm-blooded animal subjects, eachunit containing a predetermined quantity of active component calculatedto produce the desired therapeutic effect in association with therequired pharmaceutical diluent, carrier or vehicle. The specificationfor the novel dosage forms of this invention are indicated bycharacteristics of the active component and the particular therapeuticeffect to be achieved or the limitations inherent in the art ofcompounding such an active component for therapeutic use in warm-bloodedanimals as disclosed in this specification. Examples of suitable oraldosage forms in accord with this invention are tablets, capsules, pills,powder packets, granules, wafers, cachets, teaspoonfuls, dropperfuls,ampules, vials, segregated multiples of any of the foregoing and otherforms as herein described.

The complement inhibiting activity of the compounds of this inventionhas been demonstrated by one or more of the following identified tests:(i) Test, Code 026 (C1 inhibitor)--This test measures the ability ofactivated human C1 to destroy fluid phase human C2 in the presence of C4and appropriate dilutions of the test compound. An active inhibitorprotects C2 from C1 and C4; (ii) Test, Code 035 (C3-C9 inhibitor)--Thistest determines the ability of the late components of human complement(C3-C9) to lyse EAC 142 in the presence of appropriate dilutions of thetest compound. An active inhibitor protects EAC 142 from lysis by humanC3-C9; (iii) Test, Code 036 (C-Shunt inhibitor)--In this test humanerythrocytes rendered fragile are lysed in autologous serum via theshunt pathway activated by cobra venom factor in the presence ofappropriate dilutions of the test compound. Inhibition of the shuntpathway results in failure of lysis; (iv) Forssman VasculitisTest--Here, the well known complement dependent lesion, Forssmanvasculitis, is produced in guinea pigs by intradermal injection ofrabbit anti-Forssman antiserum. The lesion is measured in terms ofdiameter, edema and hemorrhage and the extent to which a combined indexof these is inhibited by prior intraperitoneal injection of the testcompound at 200 mg/kg is then reported, unless otherwise stated; (v)Forssman Shock Test--Lethal shock is produced in guinea pigs by an i.v.injection of anti-Forssman antiserum and the harmonic mean death time oftreated guinea pigs is compared with that of simultaneous controls; (vi)Complement Level Reduction Test--In this test, the above dosed guineapigs, or others, are bled for serum and the complement level isdetermined in undiluted serum by the capillary tube method of U.S. Pat.No. 3,876,376 and compared to undosed control guinea pigs; and (vii) Cap50 Test--Here, appropriate amounts of the test compound are added to apool of guinea pig serum in vitro, after which the undiluted serumcapillary tube assay referred to above is run. The concentration ofcompound inhibiting 50% is reported.

With reference to Table I, guinea pigs weighing about 300 g were dosedintravenously (i.v.) or intraperitoneally (i.p.) with 200 mg/kg of thetest compound dissolved in saline and adjusted to pH 7-8. One hour afterdosing, the guinea pigs were decapitated, blood was collected and theserum separated. The serum was tested for whole complement using thecapillary tube assay. Percent inhibition was calculated by comparisonwith simultaneous controls. The results appear in Table I together withresults of tests, code 026, 035, 036, Cap 50, % inhibition and Forssmanshock. Table I shows that the compounds of the invention possess highlysignificant in vitro and in vivo, complement inhibiting activity inwarm-blooded animals.

Table II indicates the complement inhibiting activity of an intermediatecompound of the invention.

                                      TABLE I                                     __________________________________________________________________________    Biological Activities                                                                                                In Vivo Activity                                                              (Guinea Pig)                                                                  % Inhibition                                               Cl  C-Late                                                                            Shunt Inhi-                                                                              Intraperitoneal                                            026*                                                                              035*                                                                              bition 036*                                                                              Time (Minutes)                         Compound            Wells                                                                             Wells                                                                             Wells Cap 50*                                                                            30 60 120                              __________________________________________________________________________    8,8',8",8'"-{Ureylenebis{s-phenenylbis-                                       [carbonylimino(4-methyl-3,1-phenylene)-                                                           +6**                                                                              +3  +4    192  -62                                                                              -84                                                                              -95                              carbonylimino]}}tetra-1,3,5-naphthalene-                                      trisulfonic acid dodecasodium salt                                            3,3',3",3'"-{Ureylenebis[s-phenenylbis-                                       (carbonylimino)]}tetrakis[5-(4,6,8-tri-                                                           +7  +2  +5     72  -90                                                                              -94                                                                              -89                              sulfo-1-naphthyl)carbamoyl]benzoic acid                                       dodecasodium salt                                                             __________________________________________________________________________     *Code designation for tests employed as referred herein.                      **Activity in wells a serial dilution assay. Higher well number indicates     higher activity. The serial dilutions are two-fold.                      

                                      TABLE                                       __________________________________________________________________________    Biological Activities (Intermediate)                                                                                 In Vivo Activity                                                              (Guinea Pig)                                                                  % Inhibition                                               Cl  C-Late                                                                            Shunt Inhi-                                                                              Intraperitoneal                                            026*                                                                              035*                                                                              bition 036*                                                                              Time (Minutes)                         Compound            Wells                                                                             Wells                                                                             Wells Cap 50*                                                                            30 60 120                              __________________________________________________________________________    3,3'-[5-Amino-m-phenylenebis(carbonyl-                                        imino)]bis{5-[4,6,8-trisulfo-1-naph-                                                              +4**                                                                              +2  +2    144  -40                                                                              -61                                                                              -61                              thyl)carbamoyl]}benzoic acid hexasodium                                       salt                                                                          __________________________________________________________________________     *Code designation for tests employed as referred herein.                      **Activity in wells a serial dilution assay. Higher well number indicates     higher activity. The serial dilutions are two-fold.                      

DETAILED DESCRIPTION OF THE INVENTION EXAMPLE 1

8,8'-{(5-nitro-1,3-phenylene)bis[carbonylimino(4-methyl-3,1-phenylene)carbonylimino]}di-1,3,5-naphthalenetrisulfonicacid hexasodium salt

To a warm solution of 106.4 g of (80.5%)8-amino-1,3,5-naphthalenetrisulfonic acid in 100 ml of water and 45.0 mlof 5N sodium hydroxide is slowly added 500 ml of absolute ethanol withvigorous stirring for 30 minutes. The mixture iw cooled to roomtemperature and filtered. The precipitate is washed with 80% aqueousethanol, ethanol and ether and is dried in vacuo at 110° C. for 16 hoursto give 103.7 g of 8-amino-1,3,5-naphthalenetrisulfonic acid trisodiumsalt.

A mixture of 25.0 g of 4-methyl-3-nitrobenzoic acid and 50 ml of thionylchloride is refluxed for 31/2 hours in a 110° C. oil bath. The resultingsolution is evaporated in vacuo to an oil. The oil is distilled at apressure of 0.5 mm of mercury and an oil bath temperature of 145°-160°C. The fraction, bp 108°-113° C., is collected to give 24.3 g of3-nitro-p-toluoyl chloride.

To a stirred solution of 22.5 g of 8-amino-1,3,5-naphthalenetrisulfonicacid trisodium salt in 160 ml of water is added 11.0 g of the precedingproduct with a small amount of ether. Stirring is continued, and afterone hour 1.0 g of sodium acetate trihydrate and 1.0 g of3-nitro-p-toluoyl chloride are added. The mixture is stirred anadditional 3 hours and the above addition of sodium acetate and3-nitro-p-toluoyl chloride is repeated. The mixture is stirred anadditional hour, acidified to Congo Red indicator paper withhydrochloric acid and filtered. The filtrate is neutralized with sodiumhydroxide, concentrated, dissolved in 50 ml of water and added to 1liter of ethanol with stirring for 16 hours. The solid is filtered andforms a gel on washing with ethanol. The gel is dissovled in water andevaporated. The residue is dissolved in 35 ml of hot water and 320 ml ofabsolute ethanol is added with stirring. The mixture solidifies andwater is added to allow filtration. The solid is washed with ether anddried in vacuo. The filtrate is treated by stirring with one liter ofethanol, the separated solid is collected, washed with ether, and driedto yield a combined total of 23.9 g of8-(3-nitro-p-toluamido)-1,3,5-naphthalenetrisulfonic acid trisodiumsalt.

A 22.0 g portion of the preceding product, 200 ml of water and 2.5 g of10% palladium-on-carbon catalyst is hydrogneated in a Parr shaker untilno more hydrogen is absorbed. The resulting mixture is filtered throughdiatomaceous earth, the residue is washed with water, and the filtrateis evaporated, the residue is dissolved in 50 ml of water and added to900 ml of absolute ethanol. The mixture is warmed on a steam bath andthen is stirred at room temperature for 3 hours. The mixture is filteredand the solid is washed with ethanol, then ether and dried in vacuo togive 16.89 g of 8-(3-amino-p-toluamido)-1,3,5-naphthalenetrisulfonicacid trisodium salt.

A mixture of 60.0 g of 5-nitroisophthalic acid, 300 ml of thionylchloride and one ml of dimethylformamide is stirred at room temperaturefor 30 minutes, then is refluxed for one hour. The resulting clearsolution is allowed to stand 24 hours, then is evaporated to a smallvolume in vacuo. The evaporation step is repeated with toluene and theresulting liquid is diluted with 250 ml of hexane. The mixture isstirred and cooled until the resulting oil is solidified. The product isground to a powder and is recrystallized twice from carbon tetrachlorideto give 47.4 g of 5-nitroisophthaloyl chloride.

A stirred solution of 10.6 g of8-(3-amino-p-toluamido)-1,3,5-naphthalenetrisulfonic acid trisodium saltin 60 ml of water is neutralized to pH 7.2, then 2.84 g of sodiumacetate trihydrate is added followed by 2.48 g of powdered5-nitroisophthaloyl chloride with vigorous stirring. Stirring iscontinued for 2 hours, the reaction mixture is filtered, and thefiltrate evaporated in vacuo. The residue is dissolved in 50 ml of hotwater and acidified to pH 2.5, then 70 ml of absolute ethanol is addedwith vigorous stirring to form a precipitate. The mixture is heateduntil solution results and then allowed to cool with stirring. Thereprecipitated product is collected, washed with 70% aqueous ethanol,ethanol and ether, then is dried to yield 10.6 g of the product of theExample.

EXAMPLE 2

8,8'-{5-amino-1,3-phenylenebis{{[carbonylimino(4-methyl-3,1-phenylene)]carbonyl}imino}}di-1,3,5-naphthalenetrisulfonicacid hexasodium salt

A mixture of 1.98 g of the product of Example 1, 60 ml of water and 500mg of 10% palladium-on-carbon catalyst is hydrogenated in a Parr shaker.The resulting mixture is filtered, and the filtrate is evaporated. Theresidue is dissolved in 12 ml of hot water and 125 ml of absoluteethanol is added. The precipitate is collected, washed with ethanol andether and dried to yield 1.73 g of the product of the Example.

EXAMPLE 3

8,8',8",8'"-{ureylenebis{s-phenenylbis[carbonylimino(4-methyl-3,1-phenylene)carbonylimino]}}tetra-1,3,5-naphthalenetrisulfonicacid dodecasodium salt

Phosgene gas is bubbled into a mixture of 1.73 g of the product ofExample 2, 290 mg of sodium carbonate and 20 ml of water until acidic toCongo Red indicator paper. The mixture is adjusted to pH 7.0 andfiltered. The filtrate is evaporated. The residue is dissolved in 10 mlof hot water, then ethanol is added producing a gum. The supernatant isdecanted, the gum is triturated with ethanol and solidifies. The solidis collected by filtration, washed with ethanol and ether and dried. Thematerial is dissolved in 15 ml of water, reprecipitated with 50 ml ofethanol, stirred for 1 hour, filtered, washed as above and dried toyield 1.5 g of the product of the Example.

EXAMPLE 4

3,3'-[5-nitro-m-phenylenebis(carbonylimino)]bis-{5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]}benzoicacid hexasodium salt

A 35.0 g portion of 5-nitroisophthaloyl chloride is added to 600 ml ofmethanol with stirring producing a precipitate. The mixture is heated tosolution then is chilled, filtered and dried to yield 31.75 g ofdimethyl 5-nitroisophthalate.

A mixture of 7.46 g of potassium hydroxide in 87.5 ml of methanol isadded to a stirred solution of 31.75 g of the preceding product in 331.0ml of acetone. A solid is precipitated and stirring is continued for 16hours. The solid (A) is filtered off, washed with ether and set aside.The filtrate is evaporated, the residue is extracted with 125 ml of warmwater and is filtered. The filtrate is acidified with dilutehydrochloric acid to produce a precipitate which is collected and driedto yield 3.4 g of product. The solid (A) above is extracted with 250 mlof warm water and is filtered. The filtrate is filtered again at roomtemperature, acidified with dilute hydrochloric acid and cooled. Theprecipitate is collected and dried to give 18.25 g of additional productidentified as 5-nitro-isophthalic acid, 3-methyl ester.

A mixture of 18.38 g of the product above, 60 ml of thionyl chloride and0.37 ml of dimethylformamide is heated at 60° C. for 2.5 hours. Thesolution is evaporated, then is treated with toluene, and again isevaporated. The residue is slurried in hot diethyl ether and the ethervolume is reduced by evaporation. The mixture is chilled and filtered.The precipitate is washed with cold ether and is dried. The material isextracted with 500 ml of boiling hexane by decantation. The hexane iscooled and filtered to yield 14.1 g of 3-carbomethoxy-5-nitrobenzoylchloride.

To a solution of 14.0 g of 8-amino-1,3,5-naphthalenetrisulfonic acidtrisodium salt and 8.96 g of sodium acetate trihydrate in 150 ml ofwater is added with stirring 8.0 g of 3-carbomethoxy-5-nitrobenzoylchloride. Stirring is continued for 2 hours then 18.0 ml of diethylether is added and stirring is continued for one additional hour. Anadditional 1.12 g of sodium acetate is added along with 1.0 g of3-carbomethoxy-5-nitrobenzoyl chloride with continued stirring for onehour. The mixture is filtered and the filtrate is concentrated. Theresidue is dissolved in 100 ml of hot water, 100 ml of absolute ethanolis added with formation on standing of a precipitate. The material isfiltered, washed with 80% aqueous ethanol, ethanol and ether and driedto yield 17.35 g of 5-nitro-N-4,6,8-trisulfo-1-naphthylisophthalamicacid methyl ester trisodium salt.

A 12.0 g portion of the above product in 183.0 ml of 0.1N sodiumhydroxide is stirred for 3 hours. The solution is acidified to pH 2.0with dilute hydrochloric acid then is evaporated. The residue isdissolved in 35 ml of hot water and 350 ml of absolute ethanol is added.The precipitated product is filtered, washed with ethanol and ether anddried to yield 11.0 g of5-nitro-N-4,6,8-trisulfo-1-naphthylisophthalamic acid trisodium salt

A mixture of 11.0 g of the preceding compound and 2.0 g of 10%palladium-on-carbon catalyst in 100 ml of water is hydrogenated in aParr shaker until no additional hydrogen is absorbed. The resultingmixture is filtered through diatomaceous earth, the filtrate isevaporated, the residue is dissolved in 35 ml of hot water, then isdiluted with 350 ml of aboslute ethanol to yield a precipitate. Theproduct is collected, washed with ethanol and ether, and dried to give8.6 of 5-amino-N-4,6,8-trisulfo-1-naphthylisophthalamic acid trisodiumsalt.

A stirred solution of 8.6 g of the above compound in 50 ml of water isneutralized to pH 7.2, then 2.2 g of sodium acetate trihydrate is addedfollowed by 1.92 g of powdered 5-nitroisophthaloyl chloride withvigorous stirring. Stirring is continued for an additional 3 hours thenthe reaction mixture is filtered and evaporated in vacuo. The residue isdissolved in 50 ml of water and acidified to pH 2.0 A solid isprecipitated by the slow addition of 120 ml of absolute ethanol withstirring for 1/2 hour. The solid is filtered, washed with 80% aqueousethanol, ethanol and ether and dried in vacuo to yield 10.1 g of theproduct of the Example.

EXAMPLE 5

3,3'-[5-amino-m-phenylenebis(carbonylimino)]bis{5-[4,6,8-trisulfo-1-naphthyl)carbamoyl]}benzoicacid hexasodium salt

A mixture of 9.1 g of the product of Example 4, 1.3 g of 10%palladium-on-carbon catalyst and 150 ml of water is hydrogenated in aParr shaker until no additional hydrogen is absorbed. The resultingmixture is filtered through a diatomaceous earth. The filtrate isevaporated, the residue is dissolved in 50 ml of hot water and 500 ml ofabsolute ethanol is added with stirring. Stirring is continued for 1hour. The product is filtered, washed with ethanol and ether and driedto yield 7.3 g of the product of the Example.

EXAMPLE 6

3,3',3",3'"-{ureylenebis[s-phenenylbis(carbonylimino)]}-tetrakis[5-(4,6,8-trisulfo-1-naphthyl)carbamoyl]benzoicacid dodecasodium salt

Phosgene gas is bubbled into a solution of 6.6 g of the product ofExample 5 and 1.56 g of sodium carbonate in 60.0 ml of water untilacidic to Congo Red indicator paper. The mixture is adjusted to pH 7.2with sodium carbonate, treated with activated charcoal and filtered. Thefiltrate is concentrated and the residue is dissolved in 40.0 ml of hotwater then ethanol is added to a volume of 140 ml to form a gum. Thesupernatant is decanted and the gum is triturated with ethanol to yielda solid. The solid is filtered, washed with ethanol and ether and dried.The material is dissovled in 40.0 ml of hot water and is added to 140 mlof ethanol to again give a gum. The gum is collected, dissolved in waterand evaporated. The residue is dissolved in 50 ml of water, adjusted topH 2.0 with hydrochloric acid and treated with 140 ml of ethanol. Thesupernatant is decanted and the residue is triturated with ethanol,filtered, washed with ethanol and ether and dried to yield 5.1 g of theproduct of the Example as a tan solid.

EXAMPLE 7

    ______________________________________                                        Preparation of Compressed Tablet                                              Ingredient              mg/Tablet                                             ______________________________________                                        Active Compound         0.5-500                                               Dibasic Calcium Phosphate N.F.                                                                        qs                                                    Starch USP              40                                                    Modified Starch         10                                                    Magnesium Stearate USP  1-5                                                   ______________________________________                                    

EXAMPLE 8

    ______________________________________                                        Preparation of Compressed Tablet - Sustained Action                           Ingredient             mg/Tablet                                              ______________________________________                                        Active Compound        0.5-500(as acid                                        as Aluminum Lake*, Micronized                                                                        equivalent)                                            Dibasic Calcium Phosphate N.F.                                                                       qs                                                     Alginic Acid           20                                                     Starch USP             35                                                     Magnesium Stearate USP 1-10                                                   ______________________________________                                         *Complement inhibitor plus aluminum sulfate yields aluminum complement        inhibitor. Complement inhibitor content in aluminum lake ranges from          5-30%.                                                                   

EXAMPLE 9

    ______________________________________                                        Preparation of Hard Shell Capsule                                             Ingredient            mg/Capsule                                              ______________________________________                                        Active Compound       0.5-500                                                 Lactose, Spray Dried  qs                                                      Magnesium Stearate    1-10                                                    ______________________________________                                    

EXAMPLE 10

    ______________________________________                                        Preparation of Oral Liquid (Syrup)                                            Ingredient             % W/V                                                  ______________________________________                                        Active Compound        0.05-5                                                 Liquid Sugar           75.0                                                   Methyl Paraben USP     0.18                                                   Propyl Paraben USP     0.02                                                   Flavoring Agent        qs                                                     Purified Water qs ad   100.0                                                  ______________________________________                                    

EXAMPLE 11

    ______________________________________                                        Preparation of Oral Liquid (Elixir)                                           Ingredient             % W/V                                                  ______________________________________                                        Active Compound        0.05-5                                                 Alcohol USP            12.5                                                   Glycerin USP           45.0                                                   Syrup USP              20.0                                                   Flavoring Agent        qs                                                     Purified Water qs ad   100.0                                                  ______________________________________                                    

EXAMPLE 12

    ______________________________________                                        Preparation of Oral Suspension (Syrup)                                        Ingredient            % W/V                                                   ______________________________________                                        Active Compound       0.05-5                                                  as Aluminum Lake, Micronized                                                                        (acid equivalent)                                       Polysorbate 80 USP    0.1                                                     Magnesium Aluminum Silicate,                                                  Colloidal             0.3                                                     Flavoring Agent       qs                                                      Methyl Paraben USP    0.18                                                    Propyl Paraben USP    0.02                                                    Liquid Sugar          75.0                                                    Purified Water qs ad  100.0                                                   ______________________________________                                    

EXAMPLE 13

    ______________________________________                                        Preparation of Injectable Solution                                            Ingredient             % W/V                                                  ______________________________________                                        Active Compound        0.05-5                                                 Benzyl Alcohol N.F.    0.9                                                    Water for Injection    100.0                                                  ______________________________________                                    

EXAMPLE 14

    ______________________________________                                        Preparation of Injectable Oil                                                 Ingredient            % W/V                                                   ______________________________________                                        Active Compound       0.05-5                                                  Benzyl Alcohol        1.5                                                     Sesame Oil qs ad      100.0                                                   ______________________________________                                    

EXAMPLE 15

    ______________________________________                                        Preparation of Intra-Articular Product                                        Ingredient               Amount                                               ______________________________________                                        Active Compound          2-20 mg                                              NaCl (physiological saline)                                                                            0.9%                                                 Benzyl Alcohol           0.9%                                                 Sodium Carboxymethylcellulose                                                                          1-5%                                                 pH adjusted to 5.0-7.5                                                        Water for Injection qs ad                                                                              100%                                                 ______________________________________                                    

EXAMPLE 16

    ______________________________________                                        Preparation of Injectable Depo Suspension                                     Ingredient            % W/V                                                   ______________________________________                                        Active Compound       0.05-5                                                                        (acid equivalent)                                       Polysorbate 80 USP    0.2                                                     Polyethylene Glycol 4000 USP                                                                        3.0                                                     Sodium Chloride USP   0.8                                                     Benzyl Alcohol N.F.   0.9                                                     HCl to pH 6-8         qs                                                      Water for Injection qs ad                                                                           100.0                                                   ______________________________________                                    

We claim:
 1. A compound of the formula: ##STR8## wherein R is selectedfrom the group consisting of hydrogen and methyl; R₁ is selected fromthe group consisting of hydrogen and carboxyl; A is a pharmaceuticallyacceptable salt cation.
 2. A compound according to claim 1, wherein R₁is hydrogen; and R and A are as previously defined.
 3. A compoundaccording to claim 1, wherein R₁ is carboxyl; and R and A are aspreviously defined.
 4. A compound according to claim 3, wherein A issodium.
 5. The compound according to claim 1, 8,8',8",8'"-{ureylenebis{s-phenenylbis[carbonylimino(4-methyl-3,1-phenylene)carbonylimino]}}tetra-1,3,5-naphthalenetrisulfonicacid dodecasodium salt.
 6. The compound according to claim 1,3,3',3",3'"-{ureylenebis[s-phenenylbis(carbonylimino]}tetrakis[5-(4,6,8-trisulfo-1-naphthyl)carbamoyl]benzoic acid dodecasodium salt.